The NeuroEM Story
Like Post-It Notes and penicillin, NeuroEM originated from an unexpected discovery in the lab.
What began as an experiment expecting negative effects instead turned into a revolutionary breakthrough—one that could reshape how neurodegenerative diseases are treated, moving beyond pharmaceuticals to a non-invasive, technology-driven approach.
In 2013, Dr. Gary Arendash, a neuroscientist studying Alzheimer’s disease, set out to test a hypothesis: that prolonged exposure to electromagnetic waves—similar to those emitted by cellular phones—would accelerate neurodegeneration in Alzheimer’s mouse models. He expected to find evidence of cognitive decline and further proof of environmental risk factors for the disease.
Instead, he found the exact opposite. Rather than harming the mice, the electromagnetic waves prevented and even reversed their cognitive impairments. Further analysis revealed that these waves were breaking down amyloid-beta plaques and tau tangles—the toxic proteins that drive Alzheimer’s disease—while simultaneously enhancing neuronal function.
This groundbreaking discovery led Dr. Arendash to pivot entirely from his original hypothesis and focus on developing a non-invasive, wearable therapeutic device capable of delivering Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) to humans.
Recognizing the immense potential of TEMT-RF, NeuroEM Therapeutics was founded to bring this technology from the lab to real-world clinical use. Initial preclinical studies further confirmed TEMT-RF’s ability to restore cognitive function, leading to a landmark human feasibility study in 2019 that demonstrated significant cognitive improvement in Alzheimer’s patients.
